Back to Search Start Over

Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab.

Authors :
Narita, Tomohiko
Oiso, Naoki
Taketomo, Yasunori
Okahashi, Kazunori
Yamauchi, Kohei
Sato, Masako
Uchida, Shusuke
Matsuda, Hiromasa
Kawada, Akira
Source :
Journal of Dermatology; Feb2016, Vol. 43 Issue 2, p210-214, 5p
Publication Year :
2016

Abstract

Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab-associated adverse events include organ-specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin-dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab-related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03852407
Volume :
43
Issue :
2
Database :
Complementary Index
Journal :
Journal of Dermatology
Publication Type :
Academic Journal
Accession number :
112505901
Full Text :
https://doi.org/10.1111/1346-8138.13028